LGVN Longeveron Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$0.73

Period return

+0.14 (+23.10%)

Volume

306.3K

2026-06-05O $0.8 H $0.8 L $0.72 C $0.73MA5 $0.77MA20 $0.76MA60 $0.91MA120 $0.74

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 12.MediumHOLD26 days ago
Maxim Group: Hold
US analyst rating / recommendation change.
2026. 05. 04.LowBUYlast month
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 08. 16.LowBUY10 months ago
Roth Capital: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $7.15 · 3 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Sector: Healthcare
Industry: Biotechnology
HQ: Miami, FL, United States
Fiscal year end: —
Employees: 38
IPO date: —

View details →